Cue Biopharma, Inc. (CUE): Total Liabilities
$15.78M
As of 2025-12-31
$28.40M
As of 2026-06-30
-14.9%
3-year compound annual growth
-5.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.78M | +7.4% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $14.69M | -39.9% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $24.45M | -4.5% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $25.60M | +43.0% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $17.91M | -13.2% | 2023-03-21, Balance as of period end |
| 2020-12-31 | $20.62M | +21.2% | 2022-03-16, Balance as of period end |
| 2019-12-31 | $17.02M | +49.4% | 2021-03-09, Balance as of period end |
| 2018-12-31 | $11.39M | +113.1% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $5.35M | n/a | 2019-03-14, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $15.78M | +7.4% |
| Celularity Inc (CELU) | 2025-12-31 | $145.39M | +17.4% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $71.25M | -27.0% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $306.60M | -7.0% |
| Verastem, Inc. (VSTM) | 2025-12-31 | $189.25M | +45.1% |
| Alumis Inc. (ALMS) | 2025-12-31 | $110.64M | +36.8% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $11.64M | -0.5% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $85.85M | -19.9% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $22.39M | -65.0% |
Compare CUE, CELU, TRDA, FHTX side by side · Screen every company in Pharmaceutical Preparations ↗